Approved by the Food and Drug Administration on February 13, 2024. NALIRIFOX, a combination chemotherapy for first-line treatment of metastatic pancreatic adenocarcinoma.
Dr. Patrick BolandI am a medical oncologist. Gastrointestinal Oncology Program We conduct research at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, New Jersey’s leading cancer program and the only National Cancer Institute (NCI) designated comprehensive cancer center. Dr. Borland’s clinical expertise includes gastrointestinal malignancies, colorectal cancer, anal cancer, gastroesophageal cancer, euroendocrine tumors, and pancreatic cancer. He is available to share more about what this FDA approval of his means for patients.